Curcumin

Curcumin, the primary bioactive compound in turmeric, has been studied across a wide range of health outcomes including inflammation, joint health, metabolic health, aging, and skin. The overall body of evidence is mixed in quality: while multiple meta-analyses and systematic reviews exist, many individual trials are small, short in duration, and use inconsistent formulations. The strongest and most consistent signal in the human literature relates to curcumin's anti-inflammatory and antioxidant effects, and its potential benefits for joint pain and function in osteoarthritis populations. Several meta-analyses and systematic reviews in the retrieved literature address curcumin's effects on inflammatory biomarkers and osteoarthritis symptoms. These higher-quality sources suggest that curcumin supplementation can reduce markers of inflammation and modestly improve pain and physical function in adults with osteoarthritis, though effect sizes are generally modest and head-to-head comparisons with standard treatments are limited. Mechanistically, curcumin is understood to inhibit NF-κB signaling and reduce pro-inflammatory cytokines such as IL-1β and TNF-α, and to inhibit COX-2 — pathways supported primarily by preclinical research that broadly aligns with clinical observations. A notable formulation issue emerges repeatedly: standard curcumin has very poor oral bioavailability, and co-administration with piperine (from black pepper) has been reported to substantially enhance absorption, though the frequently cited figure of ~2000% enhancement comes from a single older pharmacokinetic study and should be interpreted with caution. Several important limitations temper these findings. The majority of retrieved articles are narrative or scoping reviews rather than original trials, and even the meta-analyses are constrained by heterogeneity in curcumin formulations, doses, and populations studied. Many promising applications — including mental health, longevity, endometriosis, lupus, and skin health — are supported primarily by preclinical data or low-quality clinical evidence, and should not be considered established benefits in humans. Long-term safety data in diverse populations remain limited. Additionally, because most studies use proprietary or enhanced bioavailability formulations, findings may not generalize to standard turmeric powder consumed as a food spice.